TIAA Trust National Association increased its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 24.5% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 119,923 shares of the biopharmaceutical company's stock after acquiring an additional 23,625 shares during the period. TIAA Trust National Association's holdings in Bristol Myers Squibb were worth $7,314,000 at the end of the most recent reporting period.
A number of other large investors have also modified their holdings of BMY. Ameriprise Financial Inc. increased its holdings in shares of Bristol Myers Squibb by 59.9% in the 4th quarter. Ameriprise Financial Inc. now owns 32,079,246 shares of the biopharmaceutical company's stock worth $1,814,341,000 after acquiring an additional 12,011,983 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its holdings in shares of Bristol Myers Squibb by 701.2% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,470,106 shares of the biopharmaceutical company's stock worth $705,309,000 after acquiring an additional 10,913,708 shares during the period. Northern Trust Corp increased its stake in Bristol Myers Squibb by 16.2% during the 4th quarter. Northern Trust Corp now owns 24,658,360 shares of the biopharmaceutical company's stock valued at $1,394,677,000 after buying an additional 3,431,248 shares during the period. Adage Capital Partners GP L.L.C. increased its stake in Bristol Myers Squibb by 72.9% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 7,769,227 shares of the biopharmaceutical company's stock valued at $439,427,000 after buying an additional 3,275,061 shares during the period. Finally, Capital International Investors increased its stake in Bristol Myers Squibb by 7.5% during the 4th quarter. Capital International Investors now owns 45,866,624 shares of the biopharmaceutical company's stock valued at $2,593,940,000 after buying an additional 3,218,865 shares during the period. Institutional investors and hedge funds own 76.41% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities analysts have commented on the stock. Daiwa America cut shares of Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research note on Tuesday. Citigroup reduced their price objective on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating for the company in a research report on Friday, August 1st. William Blair reiterated a "market perform" rating on shares of Bristol Myers Squibb in a report on Friday, April 25th. Wall Street Zen cut shares of Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a report on Friday, June 6th. Finally, Piper Sandler began coverage on shares of Bristol Myers Squibb in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 target price for the company. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Bristol Myers Squibb currently has an average rating of "Hold" and a consensus price target of $56.38.
Check Out Our Latest Report on Bristol Myers Squibb
Bristol Myers Squibb Stock Performance
BMY stock traded down $0.05 on Thursday, reaching $44.77. 775,925 shares of the company were exchanged, compared to its average volume of 13,449,983. Bristol Myers Squibb Company has a 12 month low of $42.96 and a 12 month high of $63.33. The stock's fifty day moving average price is $47.41 and its 200 day moving average price is $52.06. The firm has a market capitalization of $91.13 billion, a PE ratio of 18.14, a PEG ratio of 2.35 and a beta of 0.36. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11.
Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, beating the consensus estimate of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The company had revenue of $12.27 billion for the quarter, compared to the consensus estimate of $11.32 billion. During the same quarter in the previous year, the company earned $2.07 EPS. The firm's revenue for the quarter was up .6% compared to the same quarter last year. On average, research analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.
Bristol Myers Squibb Announces Dividend
The company also recently declared a quarterly dividend, which was paid on Friday, August 1st. Investors of record on Thursday, July 3rd were given a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.5%. The ex-dividend date was Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 100.00%.
Bristol Myers Squibb Profile
(
Free Report)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Featured Stories

Before you consider Bristol Myers Squibb, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.
While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report